The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia

Documenti analoghi

• Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
  Pubblicazione: (2013)
• Impact of BCR-ABL mutations on patients with chronic myeloid leukemia
  di: Hochhaus, Andreas, et al.
  Pubblicazione: (2011)
• Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation
  di: Sigl, Michael, et al.
  Pubblicazione: (2013)
• BCR-ABL+ acute myeloid leukemia: are we always dealing with a high-risk disease?
  di: Neuendorff, Nina Rosa, et al.
  Pubblicazione: (2018)
• A two-fold rise of BCR-ABL transcript levels advises BCR-ABL mutation analysis in imatinib-treated chronic myeloid leukemia (CML): an analysis of the randomized CML-study IV
  Pubblicazione: (2014)